Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 48c

August 6, 2019 4:16 PM
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.05, $0.48 better than the analyst estimate of $3.57. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Earnings Guidance Management Comments

Next Articles